Muhammad Faizan Ali, MD1, Aagamjit Singh, MBBS2, Husnain Ahmad, MBBS3, Aleena Sharif, MBBS4, Usman Bin Hameed, MD5, Mujtaba Moazzam, MBBS6, Iman Ali, MBBS7, Ayesha Sharif, MD8, Sherif Eltawansy, MD9 1Jinnah Postgraduate Medical Centre, Karachi, Sindh, Pakistan; 2William Beaumont Hospital, Troy, MI; 3Shalamar Institute of Health Sciences, Lahore, Punjab, Pakistan; 4Sheikh Zayed Medical College Raheem Yar Khan, Bahawalpur, Punjab, Pakistan; 5Corewell Health William Beaumont University Hospital, Royal Oak, MI; 6William Beaumont Hospital, Royal Oak, MI; 7Shahida Islam Medical College, Bahawalpur, Punjab, Pakistan; 8William Beaumont hospital, Royal Oak, MI; 9Jersey Shore University Medical Center, Jersey Shore, NJ Introduction: Hyperglycemia is a growing metabolic risk factor for liver cancer, but its burden across age, sex, and socio-demographic index (SDI) levels remains undercharacterized. This study aims to assess liver cancer mortality and disability attributable to hyperglycemia using the 2021 Global Burden of Disease (GBD) Study. Methods: GBD 2021 data were analyzed from 1990–2021 to estimate liver cancer deaths, disability-adjusted life years (DALYs), and years of life lost (YLLs) attributable to hyperglycemia. Trends were stratified by age, sex, and SDI, using Average Annual Percent Change (AAPC) with 95% confidence intervals. Results: Globally, men experienced a higher burden of liver cancer attributable to hyperglycemia compared to women, with 3.21 million vs. 2.83 million DALYs, respectively. The age-adjusted DALY rate increased more rapidly in men than in women (AAPC: 2.94 vs. 2.68). Similarly, men had a higher total number of deaths (133,685 vs. 131,616), with mortality rates rising more steeply among men (AAPC: 3.26 vs. 3.01). The YLLs burden was also greater in men (3.18 million) compared to women (2.81 million), with a faster increase observed in men (AAPC: 2.94 vs. 2.67). Age-stratified analysis showed that individuals aged ≥70 years experienced the most significant rise in DALYs, mortality rates, and YLLs (AAPC: 1.95, 2.13, and 1.95, respectively), followed by the 50–69 age group (AAPC: 1.43, 1.49, and 1.43) and the 15–49 age group (AAPC: 1.37, 1.42, and 1.36). When stratified by SDI, countries in the low-middle SDI category demonstrated the fastest increases in DALY rates (AAPC: 3.87), mortality rates (AAPC: 3.95), and YLLs (AAPC: 3.86), followed by countries in the high and middle SDI categories. Discussion: The global burden of liver cancer attributable to hyperglycemia has risen substantially over the past three decades, with disproportionately higher impacts among men, older adults, and populations in low-middle SDI countries. These findings highlight the urgent need for targeted public health interventions and glycemic control strategies, particularly in high-risk demographic and socio-economic groups, to mitigate the growing liver cancer burden.
Disclosures: Muhammad Faizan Ali indicated no relevant financial relationships. Aagamjit Singh indicated no relevant financial relationships. Husnain Ahmad indicated no relevant financial relationships. Aleena Sharif indicated no relevant financial relationships. Usman Bin Hameed indicated no relevant financial relationships. Mujtaba Moazzam indicated no relevant financial relationships. Iman Ali indicated no relevant financial relationships. Ayesha Sharif indicated no relevant financial relationships. Sherif Eltawansy indicated no relevant financial relationships.
Muhammad Faizan Ali, MD1, Aagamjit Singh, MBBS2, Husnain Ahmad, MBBS3, Aleena Sharif, MBBS4, Usman Bin Hameed, MD5, Mujtaba Moazzam, MBBS6, Iman Ali, MBBS7, Ayesha Sharif, MD8, Sherif Eltawansy, MD9. P1552 - Hyperglycemia-Associated Liver Cancer: Global Disparities Across Age, Sex, and Development Levels in the 2021 GBD Study, ACG 2025 Annual Scientific Meeting Abstracts. Phoenix, AZ: American College of Gastroenterology.
